Northern Trust
EIDX

Northern Trust’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Northern Trust’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-136,117
Closed -$17.9M – 4542
2020
Q4 		$17.9M Sell
136,117
-2,543
-2% -$225K ﹤0.01% 1862
2020
Q3 		$7.01M Buy
138,660
+2,640
+2% +$119K ﹤0.01% 2323
2020
Q2 		$6.48M Sell
136,020
-4,665
-3% -$217K ﹤0.01% 2360
2020
Q1 		$6.89M Buy
140,685
+750
+0.5% +$38.2K ﹤0.01% 2120
2019
Q4 		$8.03M Sell
139,935
-3,618
-3% -$179K ﹤0.01% 2321
2019
Q3 		$5.16M Sell
143,553
-40,562
-22% -$1.58M ﹤0.01% 2535
2019
Q2 		$5.72M Buy
184,115
+2,647
+1% +$71.8K ﹤0.01% 2491
2019
Q1 		$4.25M Buy
181,468
+86,867
+92% +$1.39M ﹤0.01% 2650
2018
Q4 		$1.3M Buy
94,601
+4,594
+5% +$58K ﹤0.01% 3263
2018
Q3 		$898K Buy
90,007
+76,182
+551% +$1.25M ﹤0.01% 3498
2018
Q2 		$281K Buy
+13,825
New +$290K ﹤0.01% 3749

Northern Trust's EIDX Position: Q1 2021 in Review

Northern Trust sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 136,117 shares — an estimated $17.9M sold.

Northern Trust first reported a position in EIDX in Q2 2018 and held it in 11 quarters. The position peaked at $17.9M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Northern Trust reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Northern Trust sold 136,117 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $17.9M.
  • Northern Trust first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 11 quarters.
  • Northern Trust's Eidos Therapeutics, Inc. Common Stock position peaked at $17.9M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Northern Trust's 13F filing for Q1 2021, filed 12 May 2021.